Items Tagged ‘Rubraca’

March 4, 2019

FDA Approves Keytruda for Adjuvant Treatment of Melanoma

By

On February 15, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA®, Merck) for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection. Approval was based on EORTC1325/KEYNOTE‑054 (NCT02362594), a randomized, double-blind, placebo-controlled, trial in 1019 patients with completely resected, stage IIIA (>1 mm lymph node metastasis), IIIB or IIIC […]

View full entry

Tags: Melanoma, News, Ovarian Cancer, Rubraca


April 9, 2018

Rubraca® Approved as Maintenance Treatment of Recurrent Ovarian Cancer

By

CancerConnect News: Rubraca® (rucaparib) has been approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication. About Rubraca® Rubraca® is […]

View full entry

Tags: cancer treatment, News, ovarian, Ovarian Cancer, poly ADP-ribose polymerase (PARP) inhibitor, recurrent, Rubraca, treatment


January 18, 2018

Rubraca Significantly Improves Survival Ovarian Cancer

By

CancerConnect News: According to the results of a recently published clinical trail the novel precision cancer medicine Rubraca® (rucaparib) improves the outcomes of individuals with advanced ovarian cancer. About Rubraca® Rubraca® is an oral taken poly ADP-ribose polymerase (PARP) inhibitor that works by blocking PARP1, PARP2 and PARP3 enzyme involved in repairing damaged DNA. By […]

View full entry

Tags: News, Ovarian Cancer, Rubraca